GHRP-2 — Safety, Research, Risks & Legal Status

Not medical advice. GHRP-2 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	growth hormone releasing peptide 2, pralmorelin, KP-102
Category	Peptide
not_fda_approved	Research chemical; never approved for general human use in the US
milder_appetite_than_ghrp6	Appetite stimulation reported as less pronounced than GHRP-6
synergistic_with_ghrh	Combined GHRP-2 and GHRH dosing enhances GH release in research
US legal status	GHRP-2 (pralmorelin) is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption. It has been used as a diagnostic agent in some countries but has no general US approval. It is prohibited at all times in sport under the WADA list.

What is GHRP-2?

GHRP-2 is a synthetic growth hormone secretagogue peptide that acts on the ghrelin/GHS receptor to stimulate pituitary release of growth hormone. It is also known as pralmorelin and has been studied as a diagnostic probe of GH secretion. GHRP-2 is a structural analog of GHRP-6 with similar mechanisms but somewhat different pharmacokinetics and side-effect profiles.

How it works

GHRP-2 is a ligand for the growth hormone secretagogue receptor (GHS-R/ghrelin receptor) on anterior pituitary somatotroph cells and elsewhere in the hypothalamic-pituitary-gonadal axis. Its binding triggers intracellular signaling cascades that promote GH synthesis and release. GHRP-2 works synergistically with GHRH, and combined stimulation yields greater GH elevations than either agent alone.

Background & history

GHRP-2 was developed alongside GHRP-6 in the late 1980s and early 1990s as part of research into synthetic GHS compounds. Pralmorelin, a branded form of GHRP-2, was used diagnostically in some European and Asian markets to assess pituitary GH reserve. It never gained broad FDA approval in the US and remains a research chemical.

What the research says

Research and small human studies report that GHRP-2 reliably increases growth hormone and IGF-1 levels and has been investigated as a diagnostic test of pituitary function. It also stimulates appetite, though less strongly than GHRP-6, and robust evidence for long-term therapeutic use is limited. Some research suggests potential roles in elderly populations or GH insufficiency, but human data remain preliminary.

Reported effects

Reported increase in growth hormone secretion
Studied increases in IGF-1 levels
Reported appetite stimulation, generally milder than GHRP-6
Studied as a diagnostic probe of pituitary GH reserve
Reported effects on prolactin and cortisol secretion
Studied synergistic effects when combined with GHRH

Dosing & administration (informational)

In diagnostic and research studies, GHRP-2 has been administered intravenously or subcutaneously in doses ranging from 1 to 100 micrograms per kilogram, with GH peaks typically observed within 15 to 30 minutes. Diagnostic protocols often used single provocative injections, while research protocols examined repeated dosing or infusions.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Injection carries risks of pain, bruising, infection, and injection-site reactions without sterile technique
Raising growth hormone and IGF-1 can cause insulin resistance, fluid retention, and joint pain
Elevated GH and IGF-1 are a theoretical cancer concern because IGF-1 is a growth signal
Prohibited at all times in sport under the WADA list as a GH secretagogue
Research-chemical material may be impure, mislabeled, or contaminated and lacks quality assurance
May cause carpal tunnel syndrome and other compression neuropathies with prolonged elevation

Drug & supplement interactions

Somatostatin antagonizes GHRP-2-induced GH secretion
GHRH has synergistic effects with GHRP-2 for GH release (tested in research)
Concurrent use with other GHS compounds not well-characterized
Dopaminergic and adrenergic tone influences GH response

Who should avoid it

Active malignancy or cancer history (IGF-1 elevation risk)
Uncontrolled diabetes or severe baseline glucose dysregulation
Moderate to severe sleep apnea
Acute sepsis or critical illness
Severe thyroid hormone deficiency without adequate replacement

How it is commonly combined

GHRP-2 has been combined with GHRH in research studies to achieve synergistic GH release greater than either agent alone. Such combinations are not standard practice and are not well-studied in humans outside of diagnostic contexts.

Legal & regulatory. GHRP-2 (pralmorelin) is not approved by the FDA for human use in the United States and is sold as a research chemical not for human consumption. It has been used as a diagnostic agent in some countries but has no general US approval. It is prohibited at all times in sport under the WADA list.

Quality & harm reduction

R
e
q
u
i
r
e
a
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
(
C
O
A
)
f
o
r
a
n
y
p
r
o
d
u
c
t
.
L
o
o
k
f
o
r
H
P
L
C
a
n
d
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
d
a
t
a
.
E
n
d
o
t
o
x
i
n
(
L
A
L
)
t
e
s
t
i
n
g
i
s
i
m
p
o
r
t
a
n
t
f
o
r
a
n
y
i
n
j
e
c
t
a
b
l
e
p
e
p
t
i
d
e
.
U
s
e
s
t
e
r
i
l
e
r
e
c
o
n
s
t
i
t
u
t
i
o
n
a
n
d
c
o
l
d
s
t
o
r
a
g
e
t
o
p
r
e
s
e
r
v
e
s
t
a
b
i
l
i
t
y
a
n
d
p
r
e
v
e
n
t
c
o
n
t
a
m
i
n
a
t
i
o
n
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

How is GHRP-2 different from GHRP-6?

Both stimulate growth hormone via the ghrelin receptor, but research reports GHRP-2 tends to cause less appetite stimulation than GHRP-6 while still raising GH.

Is GHRP-2 approved for use?

It is not FDA-approved for general human use in the US and is sold as a research chemical. It has been used diagnostically in some countries.

What is a safe dose?

We do not provide human dosing guidance for unapproved research chemicals.

Does GHRP-2 work with GHRH?

Research studies show that combining GHRP-2 with GHRH produces synergistic GH secretion greater than either alone, but this combination is not standard clinical practice.

Why is GHRP-2 used as a diagnostic?

Because it reliably stimulates GH release via the GHS-R, clinicians have used it as a provocative agent to test pituitary reserve and diagnose GH deficiency.

References & further reading

PubMed: GHRP-2 pralmorelin growth hormone secretion
PubMed: GHRP-2 ghrelin receptor GHS-R
WADA Prohibited List: growth hormone secretagogues
PubMed: GHRP-2 diagnostic pituitary function test
ClinicalTrials.gov: growth hormone secretagogue early clinical research